Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

New Market Research Report: Singapore Pharmaceuticals & Healthcare Report Q1 2014


Print article Print article
2013-12-27 15:13:36 - Fast Market Research recommends "Singapore Pharmaceuticals & Healthcare Report Q1 2014" from Business Monitor International, now available

The island state's consistent investment in research and development, coupled with the government's increased commitment to healthcare, will provide pharmaceutical firms opportunities -especially in light of the ageing population. Nevertheless we highlight that Singapore's small population will continue to limit the pharmaceutical market's long-term growth potential.

Headline Expenditure Projections

* Pharmaceuticals: SGD940mn (US$770mn) in 2012 to SGD1.0bn (US$790mn) in 2013; +4.9% in local currency terms and +3.3% in US dollar terms. Forecast broadly in line with Q413.
* Healthcare: SGD16.2bn (US$13.2bn) in 2012 to SGD17.8bn (US$14.2bn) in 2013; +9.4% in local currency terms and +7.7% in US dollar terms. Forecast broadly in line with Q413.

Full Report Details at
- www.fastmr.com/prod/754662_singapore_pharmaceuticals_healthcare_ ..

Risk/Reward Ratings

Singapore's Pharmaceutical

Risk/Reward Rating (RRR) score for Q114 is 62.1 out of the maximum 100 under our newly improved RRR system. The country scored above average for the majority of indicators and sub-indicators, including sector value growth, pensionable population and overall economic and political landscape. With the relatively high score, the country is ranked sixth out of the 19 key markets in the region, behind developed countries like Japan, South Korea and Australia, as well as emerging markets like China and Taiwan. In the South East Asia region, it continues to rank first due to its relatively higher score under country and industry risks.

Key Trends And Developments

* In October, two units under Singapore's Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC; A*STAR's technology transfer arm) and Exploit Technologies signed a joint research collaboration agreement with AstraZeneca to develop drugs to treat gram-negative bacterial infections. This new deal aims to reverse the global rise of antibiotic resistance.
* In September 2013, Japanese pharmaceutical company Mitsubishi Tanabe announced plans to open a new office. The office will assume responsibility for the company's operations in Singapore, which were previously handled by Mitsubishi Tanabe's Indonesian office. The company's Indonesian office will focus its energies instead on acting as a manufacturing base for the company's wider operations in South East Asia.
* Proceeding with the promise to increase the government's commitment to healthcare, during his National Day Rally, in August 2013 Singapore's Prime Minister Lee Hsien Loong announced a range of healthcare initiatives to increase patients' access to healthcare and insurance coverage.

BMI Economic View: The Singaporean economy has shown some nascent signs of life lately, with a strong services sector powering real GDP growth to a surprise 5.1% year-on-year performance in Q313. As a result of the economy's better-than-expected performance, as well as material revisions to H113 figures, we have upgraded our full-year real GDP 2013 forecast to 3.6% from 3.1% previously. That said, we believe that a somewhat middling external demand picture will likely effect a modest slowdown from the current pace of growth in 2014, and therefore retain our 3.2% forecast for next year.

BMI Political View: Singapore faces very limited political risks in the near term, and we expect the ruling People's Action Party (PAP) to retain its monopoly on power through the next two election cycles at a minimum. However, over the longer term, the city state will come under greater pressure from its citizens to become a more vibrant democracy and foster credible opposition parties, and PAP policy will likely shift towards slightly more populist measures as its popularity begins to erode.

Partial Table of Contents:

BMI Industry View
SWOT
- Political
- Economic
- Business Environment
Industry Forecast
- Pharmaceutical Market Forecast
- Table: Pharmaceutical Sales Indicators 2009-2017
- Healthcare Market Forecast
- Table: Healthcare Expenditure Indicators, 2009-2017
- Table: Healthcare Governmental Indicators, 2009-2017
- Table: Healthcare Private Indicators, 2009-2017
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators, 2009-2017
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators, 2009-2017
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators, 2009-2017
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators, 2009-2017
- Pharmaceutical Trade Forecast
- Table: Exports And Imports Indicators, 2009-2017
- Other Healthcare Data
- Key Risks To BMI's Forecast Scenario
Macroeconomic Forecasts
- Household Leverage Is A Risk...
- ...But The Overall Picture Is More Sanguine
- Higher Returns On External Assets Will Provide A Boost
- Near Term Growth Prospects Muted, But Stronger Growth On The Horizon
- Table: Singapore - Economic Activity
Industry Risk Reward Ratings
- Asia Pacific Risk/Reward Ratings
- Singapore Risk/Reward Ratings
- Rewards
- Risks
Market Overview
Industry Trends And Developments
- Epidemiology
- Table: Top Causes Of Death In Singapore
- Healthcare Sector
- Financing
- Table: Health Funding Sources In Singapore (SGDmn)
- Healthcare Insurance
- Healthcare Company Developments
- Medical Tourism
- International Healthcare Collaboration
- Research & Development
- Bioscience Sector
- Research & Development Activity
- Clinical Trials
Regulatory Development
- Regional Harmonisation
- Intellectual Property Issues
- Trade Agreements
- Pricing And Reimbursement Regime
Competitive Landscape
- Pharmaceutical Industry
- Table: Pharmaceutical Manufacturing In Singapore, 2004-2011
- Table: Singapore's Leading Healthcare And Pharmaceutical Companies According To Market Capitalisation (US$mn)
- Domestic Pharmaceutical Sector
- Foreign Industry
- Table: Multinational Pharmaceutical Firms' Presence In Singapore

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=754662&dt=t

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com